{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-164789","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.673293+00:00","generated_at":"2026-05-18T00:57:56.234450+00:00","sec_items":["1.01","2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio raises $80M equity; Q2 revenue $26.4M (+60% QoQ), ANKTIVA units up 246%","bullets":["Registered direct offering of 29.6M shares and warrants at $2.70/unit, gross proceeds ~$80M.","Q2 2025 revenue $26.4M, up 60% from Q1 2025; year-to-date sales ~$43M.","Cash and equivalents $153.7M as of June 30, 2025.","FDA refused to file supplemental BLA for papillary NMIBC; company re-evaluating approach with new data.","UK MHRA approved ANKTIVA marketing authorization; NSCLC RCT initiated in US."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-164789","json":"https://secwatch.observer/filing/0001193125-25-164789.json","markdown":"https://secwatch.observer/filing/0001193125-25-164789.md","text":"https://secwatch.observer/filing/0001193125-25-164789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/0001193125-25-164789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000119312525164789/d20571d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T00:57:56.234450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}